AavantiBio lands manufacturing partner in Friedreich's Ataxia program; NC Research Triangle lands another CDMO
AavantiBio and Resilience have announced a collaboration to manufacture a pipeline of therapies, including AavantiBio’s Friedreich’s Ataxia program, the company announced Thursday.
The adeno-associated viral vector-based candidate is currently in Phase I/II trials in the US and Europe, and Resilience will provide cell lines and viral banks for the drug’s first in-human trials. The drug will be manufactured at Resilience’s 183,000-square-foot facility in Alachua, FL.
Friedreich’s Ataxia is an inherited neuromuscular disease that can cause nervous system damage and cause patients to have trouble moving. The disease usually starts in childhood, and leads to the degeneration in the spinal cord, peripheral nerves and cerebellum.
In a statement, Resilience CEO Rahul Singhvi said:
We are excited to work with an innovative development-stage company like AavantiBio who is utilizing a unique AAV approach to address the underlying causes of rare genetic diseases. Our highly-experienced team will work collaboratively with AavantiBio on process development and analytical testing to enable a seamless transition from development to manufacturing.
NC Research Triangle lands another CDMO
Another week, another biotech has moved its manufacturing operations to North Carolina.
MedPharm, a CDMO that specializes in topical and transdermal pharmaceutical products, will open a new location in the Raleigh-Durham area, the company announced Tuesday.
The new facility will double its existing footprint, and support development, clinical and small-scale commercial manufacturing. The site is just a few miles from its current office, and will meet all FDA, EMA and GMP requirements, the company said.
In a statement, CEO Eugene Ciolfi said:
MedPharm’s investment in this facility is a clear demonstration of our continued commitment to a global vision by expanding client services downstream into commercial manufacturing. MedPharm’s newest facility is an extension of our development services and will also support our client base with their clinical and commercial pipelines needs for topical and transdermal products globally.